General anesthetics

Braxia Scientific Provides Corporate Update and Reports Fiscal Fourth Quarter and Full-Year 2021 Financial Results

Retrieved on: 
Friday, July 30, 2021
Psychoactive drugs, Drugs, Health sciences, Antidepressants, General anesthetics, Arylcyclohexylamines, Nicotinic antagonists, Sedatives, Ketamine, Therapy, Bipolar disorder, Mental health

Through its global leading researchers and experienced implementation team, Braxia Scientific has established its presence in the mental health industry.

Key Points: 
  • Through its global leading researchers and experienced implementation team, Braxia Scientific has established its presence in the mental health industry.
  • Braxia Health is the first to offer novel Ketamine therapy, including intravenous therapy, to patients in a private clinical setting in Quebec.
  • In June 2021, the Company announced that Chief Medical and Scientific Officer Dr. Joshua Rosenblat, will initiate a first-of-its-kind ketamine clinical trial to treat bipolar depression.
  • "Braxia Scientific has achieved significant milestones to date, and we are picking up the pace," noted CEO Dr. Roger McIntyre.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AcelRx, Rocket, 360 DigiTech, and Piedmont Lithium and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, July 29, 2021
Chemistry, Drugs, Chemical compounds, Anilides, General anesthetics, Janssen Pharmaceutica, Piperidines, Euphoriants, Sufentanil, Fentanyl, Lithium

The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.

Key Points: 
  • The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.
  • OnFebruary 16, 2021, AcelRx disclosed that, onFebruary 11, 2021, the Company received a warning letter from the FDA concerning promotional claims for DSUVIA.
  • For more information on the Piedmont Lithium class action go to: https://bespc.com/cases/PLL
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Ketamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured Veterans

Retrieved on: 
Thursday, July 22, 2021
Psychoactive drugs, Drugs, Neurochemistry, General anesthetics, Dissociative drugs, NMDA receptor antagonists, Nicotinic antagonists, Sedatives, Ketamine, Neurocognition, IRPS

IRP has been an early adopter of NeuroCatchs advanced brain-scanning technology to better understand brain health and neurocognitive function in patients since September of 2020.

Key Points: 
  • IRP has been an early adopter of NeuroCatchs advanced brain-scanning technology to better understand brain health and neurocognitive function in patients since September of 2020.
  • NeuroCatch is expected to remain a key part of IRPs service offering as Ketamine One expands its network to new veteran-centric markets across Canada.
  • Unique service offerings such as NeuroCatch help Ketamine Ones clinicians create more tailored treatment plans for patients, which can increase their effectiveness over time.
  • Platforms like NeuroCatch are also significant as Ketamine One embarks on embracing digital therapeutics as a core element of its competitive strategy.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AcelRx, Ocugen, Tarena, and DraftKings and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, July 22, 2021
Drugs, Chemical compounds, Anilides, General anesthetics, Janssen Pharmaceutica, Piperidines, Analgesics, Sports betting, DraftKings, Sufentanil, Fentanyl, Security

The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.

Key Points: 
  • The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.
  • misbrand Dsuvia within the meaning of the Federal Food, Drug and Cosmetic Act (FD&C Act) and make its distribution violative.
  • For more information on the DraftKings class action go to: https://bespc.com/cases/DKNG
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Core One Labs’ Akome Biotech Protects New AKO003 Ketamine-Based Breakthrough Drug Formulation For Depression Treatment

Retrieved on: 
Wednesday, July 21, 2021
Psychoactive drugs, Drugs, Antidepressants, General anesthetics, Chloroarenes, Nicotinic antagonists, Sedatives, Ketamine

VANCOUVER, British Columbia, July 21, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL) (OTC: CLABD) (Frankfurt: LD6, WKN:A3CSSU) (the “Company”) is excited to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has protected its breakthrough ketamine psychedelic drug formulation for the treatment of Depression and is set to begin further development.

Key Points: 
  • VANCOUVER, British Columbia, July 21, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL) (OTC: CLABD) (Frankfurt: LD6, WKN:A3CSSU) (the Company) is excited to announce that its wholly owned subsidiary Akome Biotech Ltd. (Akome) has protected its breakthrough ketamine psychedelic drug formulation for the treatment of Depression and is set to begin further development.
  • The formulation of Akomes breakthrough depression treatment, also known as AKO003, has now been developed and a provisional matter of composition patent application for AKO003 has been filed with the United States Patent and Trademark Office (USPTO) under application 63128302.
  • With the formula finalized the next step is the development of this drug to bring it closer to human trials and an eventual roll out to market.
  • Akomes psychedelic-based drug formulation for the treatment of depression will position Core One as a pioneer in the alternative depression treatment market, stated Joel Shacker, the Companys CEO.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AcelRx, Ocugen, Tarena, and DraftKings and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, July 15, 2021
Drugs, Chemical compounds, Anilides, General anesthetics, Janssen Pharmaceutica, Piperidines, Analgesics, Sports betting, DraftKings, Sufentanil, Fentanyl, Security

The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.

Key Points: 
  • The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.
  • misbrand Dsuvia within the meaning of the Federal Food, Drug and Cosmetic Act (FD&C Act) and make its distribution violative.
  • For more information on the DraftKings class action go to: https://bespc.com/cases/DKNG
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AcelRx, Ocugen, Tarena, and DraftKings and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, July 8, 2021
Drugs, Chemical compounds, Anilides, General anesthetics, Janssen Pharmaceutica, Piperidines, Analgesics, Sports betting, DraftKings, Sufentanil, Fentanyl, Security

The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.

Key Points: 
  • The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.
  • misbrand Dsuvia within the meaning of the Federal Food, Drug and Cosmetic Act (FD&C Act) and make its distribution violative.
  • For more information on the DraftKings class action go to: https://bespc.com/cases/DKNG
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Global Anesthetics Market Report 2020-2030: Bupivacaine; Ropivacaine; Lidocaine; Chloroprocaine; Articaine; Benzocaine; Propofol; Sevoflurane; Desflurane; Dexmedetomidine; Remifentanil; Midazolam - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021
Health, Infectious diseases, Surgery, Other Health, General Health, Pharmaceutical, Drugs, Psychoactive drugs, Medical specialties, Anesthesia, General anesthetics, NMDA receptor antagonists, Anesthetic, Local anesthetic, Ketamine, General anaesthetic

The "Anesthetics Global Market Report 2020-30: COVID-19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anesthetics Global Market Report 2020-30: COVID-19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering.
  • The anesthetics market consists of sales of drugs that cause a relaxing sensation to calm patients during surgery and remove the sensation of pain.
  • The anesthetics market is divided into general anesthetics, regional anesthetics and local anesthetics.
  • Stringent guidelines and regulations imposed by regulatory bodies are one of the important restraints for the anesthetics market.

SHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders

Retrieved on: 
Thursday, July 1, 2021
Legal, Professional services, Opioids, Drugs, Chemical compounds, Anilides, General anesthetics, Janssen Pharmaceutica, Piperidines, Euphoriants, Fentanyl, Sufentanil

AcelRx is a pharmaceutical company that develops and commercializes therapies for the treatment of acute pain.

Key Points: 
  • AcelRx is a pharmaceutical company that develops and commercializes therapies for the treatment of acute pain.
  • The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.
  • If you suffered a loss due to AcelRx Therapeutics, Inc.'s misconduct, click here .
  • On February 16, 2021, AcelRx disclosed that, on February 11, 2021, the Company received a warning letter from the FDA concerning promotional claims for DSUVIA.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AcelRx, Ocugen, and Tarena and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, July 1, 2021
Drugs, Chemical compounds, Anilides, General anesthetics, Janssen Pharmaceutica, Piperidines, Analgesics, Ethers, Sufentanil, Fentanyl

AcelRx is a specialty pharmaceutical company that focuses on the development and commercialization of therapies for the treatment of acute pain.

Key Points: 
  • AcelRx is a specialty pharmaceutical company that focuses on the development and commercialization of therapies for the treatment of acute pain.
  • The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.
  • OnFebruary 16, 2021, AcelRx disclosed that, onFebruary 11, 2021, the Company received a warning letter from the FDA concerning promotional claims for DSUVIA.
  • For more information on the Tarena class action go to: https://bespc.com/cases/TEDU
    About Bragar Eagel & Squire, P.C.